Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 22.58 AUD 1.71% Market Closed
Market Cap: 7.6B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note

Relative Value

The Relative Value of one TLX stock under the Base Case scenario is 25.49 AUD. Compared to the current market price of 22.58 AUD, Telix Pharmaceuticals Ltd is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TLX Relative Value
Base Case
25.49 AUD
Undervaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
57
vs Industry
41
Median 3Y
13.5
Median 5Y
20.7
Industry
7.7
Forward
9.7
vs History
9
vs Industry
0
Median 3Y
-18.4
Median 5Y
-23.4
Industry
22.7
Forward
124.7
vs History
26
vs Industry
0
Median 3Y
-16.3
Median 5Y
-20.3
Industry
21.6
vs History
20
vs Industry
0
Median 3Y
-14.5
Median 5Y
-18.2
Industry
25.2
vs History
52
vs Industry
1
Median 3Y
28.8
Median 5Y
21.1
Industry
2.5
vs History
57
vs Industry
35
Median 3Y
12.8
Median 5Y
20
Industry
7.7
Forward
9.6
vs History
57
vs Industry
26
Median 3Y
21.6
Median 5Y
33.7
Industry
9
vs History
9
vs Industry
0
Median 3Y
-18.1
Median 5Y
-26
Industry
4.2
Forward
64.1
vs History
9
vs Industry
0
Median 3Y
-18.1
Median 5Y
-26
Industry
4.1
Forward
76.2
vs History
25
vs Industry
0
Median 3Y
-15
Median 5Y
-19
Industry
5.7
vs History
22
vs Industry
0
Median 3Y
-13.4
Median 5Y
-17.1
Industry
3.6
vs History
68
vs Industry
10
Median 3Y
18.6
Median 5Y
16.1
Industry
4.6

Multiples Across Competitors

TLX Competitors Multiples
Telix Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Telix Pharmaceuticals Ltd
ASX:TLX
7.5B AUD 11.7 153.4 101.1 101.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/E: 199.2
153.4
3 637%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBITDA: 29.2
101.1
1 588%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBIT: 33.7
101.1
1 735%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top